Sierra Oncology (NASDAQ:SRRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $61.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Supreme Court To Decide Whether The PSLRA s Discovery Stay Applies To State Court Actions - Litigation, Mediation & Arbitration mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.